{"disease":{"id":"documented-ventricular-arrhythmias","name":"Documented ventricular arrhythmias","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"flecainide","indication_name":"Documented Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"flecainide-acetate","indication_name":"Documented Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"norpace","indication_name":"Documented ventricular arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"Disopyramide Phosphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G protein-activated inward rectifier potassium channel 4","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":"Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"norpace","guideline_body":"FDA label","recommendation":"Disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias that are life-threatening.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"norpace","guideline_body":"FDA label","recommendation":"Disopyramide phosphate is indicated for the treatment of sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"norpace","guideline_body":"FDA label","recommendation":"Disopyramide phosphate is indicated for the treatment of life-threatening ventricular arrhythmias.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}